Trials / Active Not Recruiting
Active Not RecruitingNCT06316609
Prenatal Exposure to Emerging Contaminants and Children's Atopic Dermatitis
Prenatal Exposure to Emerging Contaminants and Offspring's Atopic Dermatitis (PECCAD)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 456 (actual)
- Sponsor
- Children's Hospital of Fudan University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This prospective cohort study aims to investigate the association between prenatal blood levels of Emerging Contaminants and the five-year incidence of atopic dermatitis (AD) in offspring.
Detailed description
This prospective birth cohort study, conducted within the Shanghai prenatal population, involves the collection of maternal blood samples during gestation to directly measure the biological exposure levels of Emerging Contaminants, including Per- and Polyfluoroalkyl Substances (PFAS), Organophosphate Flame Retardants (OPFRs), and Microplastics. Serum and whole blood levels of these contaminants are evaluated during pregnancy at 12-14, 22-26, and 31-34 gestational weeks. Subsequently, the study assesses skin barrier function in infants at 24-48 hours, 42 days, and 6 months of age. During a five-year period, the occurrence of atopic dermatitis (AD) in offspring is assessed. The objectives of this cohort study are twofold: (1) to elucidate the relationship between maternal exposure to Emerging Contaminants and the development of AD in offspring, and (2) to evaluate the impact of such exposure on the skin barrier function of infants. This research aims to provide substantial evidence for the prevention of AD, offering a unique and meaningful approach to mitigating the incidence of AD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Gestational Exposure to Emerging Contaminants (ECs) | Levels of Emerging Contaminants (ECs), such as Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics, are assessed in maternal blood and umbilical cord blood during gestation. |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2018-04-30
- Completion
- 2027-12-31
- First posted
- 2024-03-18
- Last updated
- 2025-05-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06316609. Inclusion in this directory is not an endorsement.